Abstracts tagged "adam17"

Abstract Number: 1487 • ACR Convergence 2021
Type I Interferon Modulates Langerhans Cell ADAM17 in Lupus to Contribute to Photosensitivity
Thomas Li¹, Keila Veiga², Noa Schwartz³, Jose Lora⁴, Yong Liu⁴, Ali Jabbari⁵, William Shipman¹, Mehdi Rashighi⁶, James Krueger⁷, Niroshana Anandasabapathy⁴, David Oliver⁸, Yurii Chinenov⁸, Carl Blobel¹ and Theresa Lu¹, ¹Hospital for Special Surgery, New York, NY, ²New York Medical College, Hawthorne, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁴Weill Cornell Medicine, New York, NY, ⁵University of Iowa, Iowa City, IA, ⁶University of Massachusetts Medical School, Worcester, MA, ⁷Rockefeller University, New York, NY, ⁸David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Photosensitivity is a common feature in the autoimmune disease lupus erythematosus (LE) where patients develop inflammatory skin lesions in response to ultraviolet radiation (UVR).…
Abstract Number: 168 • 2020 Pediatric Rheumatology Symposium
Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity
Keila Veiga¹, Noa Schwartz ², William Shipman ¹, Marvin Sandoval ³, Thomas Li ¹, Yurii Chinenov ¹, David Oliver ¹, Ali Jabbari ⁴, James Krueger ⁵, Sarah Taber ¹, Niroshana Anandasabapathy ⁶ and Theresa Lu ¹, ¹Hospital for Special Surgery, New York, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, ³Weill Cornell Graduate School of Medical Sciences, New York, ⁴University of Iowa, Iowa City, ⁵Rockefeller Center, New York, ⁶Weill Cornell Medicine, New York
Background/Purpose: Photosensitivity resulting in inflammatory skin lesions is a hallmark of cutaneous lupus. Lesions can be disfiguring and have a negative impact on quality of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].